Scientists at VCU Massey Cancer Center have identified a protein that operates in tandem with a specific genetic mutation to spur lung cancer growth and could serve as a therapeutic target to treat the disease.
Mutations in the p53 gene are found in more than half of all cancers, but it remains difficult to effectively target the gene with drugs even decades after its discovery. Though previous research has shown that p53 acts as a tumor suppressor and initiates cancer cell death in its natural state, a new study led by Sumitra Deb, Ph.D., suggests that gain-of-function (GOF) mutations—a type of mutation where the changed gene has an added function—turn p53 into an oncogene, causing cells to replicate uncontrollably and contribute to cancer development.
Recently published in Nature Communications, the researchers determined that mutant p53 genes are empowered by a specific protein, PLK3, to copy their genetic code and promote tumor cell proliferation through a process called transactivation.
Using preclinical models of lung cancer driven by p53 GOF mutations, Deb and his research team discovered that PLK3 activates an amino acid called serine 20 (S20), a cellular building block they found to play an important role in cancer cell replication.
By inhibiting PLK3 in GOF p53 mutant cells, they observed a decrease in the function of S20 along with overall reductions in transactivation and tumor cell formation.
“Our research indicates that GOF p53 exploits PLK3 to trigger its transactivation capability and exert oncogenic functions, raising the possibility of targeting p53-driven cancer cells using PLK3 inhibitors,” said Deb, a member of the Cancer Biology research program at Massey and professor in the Department of Biochemistry and Molecular Biology at the VCU School of Medicine.
Deb’s team will continue to explore the potential for PLK3 inhibitors to be effective drugs in the treatment of lung cancer and potentially other forms of disease with the same genetic mutation.
Scientists uncover mutations that make cancer resistant to therapies targeting KRAS
Catherine A. Vaughan et al, The oncogenicity of tumor-derived mutant p53 is enhanced by the recruitment of PLK3, Nature Communications (2021). DOI: 10.1038/s41467-021-20928-8
Scientists identify protein that could serve as a therapeutic target in lung cancer (2021, April 19)
retrieved 19 April 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- Have Allergies? See If You’re at Risk for Severe COVID Vaccine Reaction - April 23, 2021
- A new method for fighting ‘cold’ tumors - April 23, 2021
- Mind Beauty on Why It's Harder to Wear a Mask in the Heat but Important Nonetheless - April 23, 2021
- Elevations RTC Highlights An Inclusive Campus Life - April 23, 2021
- The ThinOptics Vision Visionary: Gadi PontÃ - April 23, 2021
- A Plus From the Pandemic: Fewer Kids Using E-Cigarettes - April 23, 2021
- Double down on health and fitness with Garmin’s Venu 2 Series GPS smartwatch - April 23, 2021
- कोरोना संक्रमण चेन को तोड़ने में सहयोग करें जन-प्रतिनिधि: मुख्यमंत्री श्री चौहान - April 22, 2021
- Deepika Padukone’s 20-20-20 Fitness Mantra, Secret To Staying Slim Trim - April 22, 2021
- List of Top Pharma Companies in Chennai  - April 22, 2021